GlassScriptPhysician profile
Gregory S Lund
NPI 1265468342
$1,074.00
in general payments reported to CMS, 2019-2025
19 companies · $92.22 in 2025
The $92.22 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $110 · 2021: $63.83 · 2022: $135 · 2023: $109 · 2024: $104 · 2025: $92.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $189.07 | 2019 | |
| Lilly USA, LLC | $121.37 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Medtronic, INC. | $117.08 | 2021-2023 | Minimed 780g |
| Abbvie INC. | $91.26 | 2019 | |
| Tandem Diabetes Care, INC. | $89.84 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $55.28 | 2023-2024 | Ilet Bionic Pancreas |
| Astrazeneca Pharmaceuticals LP | $54.18 | 2019-2020 | |
| Lifescan, INC. | $51.62 | 2019-2022 | |
| Dexcom, INC. | $51.15 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $46.28 | 2019-2020 | |
| Mannkind Corporation | $39.05 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $35.82 | 2019-2020 | |
| Cequr Corporation | $23.66 | 2023 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $22.12 | 2025 | Yorvipath |
| Ipsen Biopharmaceuticals, INC | $21.81 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18.05 | 2020 | |
| Insulet Corporation | $17.75 | 2019 | |
| Sequel Med Tech, LLC | $17.01 | 2025 | Twiist |
| Amneal Pharmaceuticals LLC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.